UnitedHealthcare Facet Joint Injection Coverage Update

Coverage and Medical Necessity Criteria

Diagnostic injections (initial and confirmatory)

Covered when ALL of the following are met

Initial diagnostic block criteria: Pain is exacerbated by facet loading maneuvers on physical examination (e.g., hyperextension, rotation); AND clinically significant improvement has not occurred (pain remains ≥3/10) after a minimum of 4 weeks of conservative care (including but not limited to pharmacotherapy, exercise, or physical therapy); AND clinical findings and imaging suggest no other cause of the pain (e.g., spinal stenosis with neurogenic claudication, disc herniation with radicular pain, infection, tumor, fracture, pain related to prior surgery); AND the spinal motion segment is not fused; AND a radiofrequency joint denervation/ablation procedure is being considered.see text

Initial diagnostic Facet Joint Injection/Medial Branch Block

Not medically necessary / Unproven

The following are unproven and not medically necessary due to insufficient evidence:

Unproven or not medically necessary conditions: If radiofrequency ablation is not being considered at the requested level(s); OR for treating spinal pain after diagnostic injections have been completed; OR after two Facet Injections/Medial Branch Blocks at the same level and same side (considered therapeutic rather than diagnostic); OR therapeutic Facet Joint Injections and/or Medial Branch Blocks for chronic spinal pain; OR for a second Facet Joint Injection/Medial Branch Block if the initial injection did not confirm the joint as the source; OR in the presence of untreated radiculopathy at the same level as the intended diagnostic injection (except radiculopathy due to a facet joint synovial cyst); OR if injection volume for medial branch blocks exceeds 0.5 mL; OR when performed under ultrasound guidance; OR therapeutic injections at cervical, thoracic, or lumbar levels (unproven).see text

Not covered / unproven list

Diagnostic blocks — coverage with criteria

Covered when ALL of the following are met (diagnostic use):

Diagnostic block criteria: 1) Clinical selection based on history and physical examination supports potential facet-mediated pain (levels selected based on presentation and palpation); AND 2) Trial of conservative therapy per society guidance (e.g., 3 months for lumbar interventions; at least 6 weeks for cervical, individualized); AND 3) Diagnostic block demonstrates clinically significant pain reduction (commonly ≥50% considered positive, with many societies recommending ≥80% for confirmatory dual blocks); AND 4) If proceeding to radiofrequency ablation, confirmatory dual blocks may be required with documentation of percent relief and onset/duration consistent with the anesthetic used.see text

Derived from ASRA/NASS/other society guidance

Therapeutic injections — limited/insufficient evidence

Therapeutic facet joint / medial branch injections:

Therapeutic injections: Evidence is insufficient to support routine therapeutic use of intra-articular facet joint injections or medial branch blocks for long-term pain management; therapeutic MBBs are not supported by current evidence and are considered unproven/limited. Use should be reserved only for select patients with individualized justification (e.g., high risk for RFA) and documented rationale.

Based on low-quality evidence and society statements

Guidance modality — imaging considerations

Image guidance considerations:

Ultrasound guidance versus fluoroscopy/CT: There is no evidence demonstrating overall health benefit of ultrasound-guided spinal injections compared with fluoroscopy or CT; pooled analyses show increased risk of incorrect needle placement with ultrasound (approx. 11–13% RD) and ultrasound is operator-dependent. Fluoroscopy or CT is preferred for procedures requiring precise needle placement; ultrasound may be considered in select situations with experienced operators and documentation of training/justification.

Based on systematic reviews and pooled analyses

Diagnostic Medial Branch Blocks

Covered when ALL of the following are met

Diagnostic MBB dual-block requirement: Dual medial branch blocks performed in the same location(s) on two separate occasions are necessary to confirm the diagnosis due to the high false-positive rate of single injections.two separate blocks

A confirmatory second injection is indicated only if the first injection produces ≥ 80% relief and onset/duration are consistent with the agent used.

Additional diagnostic injections

Additional diagnostic considerations

Additional level testing: A second injection may be performed at a different or additional level if pain is believed to originate from a different joint and the initial block produced < 80% relief.< 80% initial relief

Therapeutic facet joint and medial branch (facet nerve) block injections at the cervical, thoracic, and lumbar levels are listed in this policy as unproven and not medically necessary because the evidence is insufficient to demonstrate efficacy and safety. Examples explicitly identified as unproven include injections performed when radiofrequency ablation is not being considered, injections after diagnostic injections have been completed (i.e., therapeutic use), repeat injections after two Facet Injections/Medial Branch Blocks at the same level/side, and procedures performed under ultrasound guidance. Additionally, medial branch block injection volumes exceeding 0.5 mL are noted as not medically necessary.

Therapeutic use claims that lack documentation of individualized justification or that are submitted as routine long‑term pain management may be denied as not medically necessary under these policy provisions.

The policy states that the routine use of therapeutic facet joint injections and therapeutic medial branch blocks for long‑term pain management is not supported due to limited and low‑quality evidence. A 2024 systematic review and meta‑analysis and guideline summaries cited in the policy characterize the therapeutic literature as mixed, of low quality, and not demonstrating consistent clinically meaningful benefit beyond short‑term outcomes. As a result, therapeutic injections as standard long‑term therapy are considered unproven and may be excluded from coverage.

When therapeutic injections are proposed, documentation should clearly justify individualized reasons (for example, high risk for RFA or other contraindications); absent such justification, requests for routine therapeutic use are considered not medically necessary.

Therapeutic medial branch blocks are described as interventions intended for long‑term pain control but the policy concludes that current evidence does not support their use as a therapeutic intervention. Multiple guideline statements (including NASS) classify the evidence as insufficient (Grade I) for many therapeutic facet procedures and note lack of high‑quality studies demonstrating meaningful long‑term benefit.

Because of this limited evidence, therapeutic MBBs offered as standard long‑term management are considered unproven and are not supported for routine coverage.

The policy lists therapeutic facet joint injections and/or medial branch blocks for treatment of chronic spinal pain as unproven and not medically necessary. It cites systematic reviews and guideline assessments that found insufficient or low‑quality evidence of durable clinical benefit; where trials exist they do not consistently show clinically meaningful improvements in pain or function beyond short follow‑up intervals.

Consequently, these procedures are excluded from routine coverage for chronic spinal pain unless individualized justification is provided and documented.

Requests that present therapeutic facet joint injections or therapeutic medial branch blocks as routine long‑term pain management are specifically identified as not medically necessary in this policy because supporting evidence of sustained efficacy is lacking. The policy highlights scenarios considered therapeutic rather than diagnostic (e.g., repeated injections at the same level/side after two prior blocks) as examples that may be denied.

Providers submitting claims for therapeutic injections should include clear rationale and supporting documentation when an individualized, non‑routine indication is claimed; otherwise the request may be considered not medically necessary.

The policy emphasizes that the use of medial branch blocks solely as a therapeutic intervention lacks supporting evidence and therefore is not supported as effective therapy. Guideline reviews referenced (including NASS) report insufficient data to recommend therapeutic MBBs for long‑term management and classify many related recommendations as Grade I (insufficient evidence).

Accordingly, therapeutic MBBs are treated as unproven in this coverage policy and are not covered as routine therapeutic treatments.

Procedure and Diagnosis Codes

Ultrasound-guided facet injection codesHCPCS

0213T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level.
0214T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure).
0215T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure).
0216T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level.
0217T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure).
0218T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure).

Fluoroscopy/CT-guided facet injection CPT codesCPT

64490	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level.
64491	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure).
64492	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure).
64493	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level.
64494	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure).
64495	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure).

ICD-10 diagnosis codes listedICD-10

M47.812	Spondylosis without myelopathy or radiculopathy, cervical region.
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region.
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region.
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region.
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region.
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region.
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified.
M47.892	Other spondylosis, cervical region.
M47.893	Other spondylosis, cervicothoracic region.
M47.894	Other spondylosis, thoracic region.

1–10 of 15

1/2

inv-17: Diagnostic block positive threshold

Diagnostic positive threshold≥ 50% pain relief for at least the expected minimum duration of the local anesthetic

Measurement basisPain reduction measured relative to the index pain (patient-reported) for duration consistent with agent used

Context of useApplies to diagnostic Facet Joint Injections and Medial Branch Blocks

inv-18: Confirmatory block pain relief threshold

Confirmatory threshold≥ 80% reduction in index pain on the second (confirmatory) block

Timing requirement

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization may be required for facet joint/medial branch procedures. Check member benefit plan, state, and federal contract requirements before scheduling. Failure to obtain required prior authorization may result in denial or reduced reimbursement.

Verify prior authorization requirements with UnitedHealthcare for the requested CPT/HCPCS codes and the member's specific plan.
Ensure prior authorization is obtained when required prior to performing diagnostic medial branch blocks, facet joint injections, or radiofrequency ablation.

Prior Authorization

Confirmatory Dual Blocks for RFA

Confirmatory dual medial branch blocks are required to validate the diagnosis prior to radiofrequency ablation (RFA) in most circumstances. Document the % pain relief and duration consistent with the local anesthetic used. A second confirmatory injection may be performed at the same location(s) when the first injection produced a positive response and to reduce false positives.

Perform dual blocks in the same location(s) on two separate occasions for confirmation prior to RFA unless clinical circumstances or payer policy indicate otherwise.

Background and Scope

Facet joint injections and medial branch blocks are described in this policy as procedures used primarily to diagnose (and in some cases to treat) facetogenic spinal pain by injecting local anesthetic with or without corticosteroid under image guidance. Diagnostic blocks are considered positive when they produce at least 50% pain relief for at least the expected duration of the local anesthetic, and documentation of onset and duration consistent with the agent used is required.

The policy further distinguishes diagnostic from therapeutic use: diagnostic injections (including confirmatory dual blocks when indicated) are covered when criteria are met, while therapeutic injections for long‑term pain management are considered unproven and not medically necessary except in select, well‑documented circumstances.

Key Definitions

inv-32: Facet Joint Injection (FJI)

DefinitionInjection of local anesthetic and/or corticosteroid into the facet joint capsule

Diagnostic positivityConsidered positive when there is at least 50% relief of pain for at least the expected minimum duration of the anesthetic

Role vs MBBCan be used diagnostically, though a Medial Branch Block is generally considered more appropriate for prognostic testing

Therapeutic useTherapeutic intra-articular facet injections are considered unproven/ not medically necessary for routine long-term pain management

inv-33: Medial Branch Block / Facet Nerve Block

DefinitionInjection of local anesthetic and/or corticosteroid along the medial branch nerves that innervate facet joints

Conservative Therapy Requirements Before Procedures

Must document failure to improve after conservative measures

Must document failure to improve after conservative measures prior to diagnostic injections:

Conservative care documented: Document a minimum of 4 weeks of conservative care (for example, appropriate pharmacotherapy, exercise, or physical therapy) with persistent pain (≥3/10) before performing diagnostic facet joint or medial branch injections.minimum 4 weeks

Medical record should include history, physical exam including facet loading maneuvers, and prior conservative therapies

Document trial of conservative therapies before proceeding

Document trial of conservative therapies before proceeding:

Conservative therapy trial: Document trial of conservative therapies (medications such as NSAIDs or other analgesics, physical therapy, and integrative treatments) prior to diagnostic or therapeutic facet procedures; recommended durations include approximately 3 months for lumbar indications and at least 6 weeks (personalized) for cervical indications.

Frequency and Quantity Limits

inv-42: Therapeutic facet joint/medial branch injections — no coverage for >2 at same level/side

Frequency limitNo coverage for more than two facet injections at the same level/side when considered therapeutic

ApplicabilityApplies to therapeutic facet joint and medial branch injections at cervical, thoracic, and lumbar levels

Denial riskAdditional (>2) therapeutic injections at the same level/side are specified as possible denial triggers

inv-43: No explicit numeric frequency limits provided in this section

Numeric frequency limitsNo explicit numeric frequency limits specified in this policy section

GuidancePolicy describes procedural limits (e.g., no >2 therapeutic injections at same level/side) but does not set repeat interval or annual caps

Image Guidance and Modality Requirements

Billing Rule

Fluoroscopy/CT preferred; ultrasound guidance not supported

Fluoroscopy or CT guidance is preferred for facet joint and medial branch block injections; ultrasound-guided facet injections are listed as unproven and are not supported by current evidence.

When precise needle placement is required, use fluoroscopy or CT guidance for claims and documentation.
Ultrasound CPT/HCPCS codes (0213T–0218T) are listed but ultrasound guidance is considered unproven in this policy.

Billing Rule

Cervical/lumbar injections — fluoroscopy/CT preferred; US operator‑dependent

For cervical and lumbar medial branch/facet joint injections fluoroscopy or CT is recommended for accuracy; ultrasound may be considered only as an operator-dependent alternative and should be supported by documentation of operator experience if used.

Cervical MBB volumes should be ≤0.3 mL (with slight variation allowed if contrast spread is inadequate).

Services Not Covered

This policy lists as not covered therapeutic facet joint and medial branch injections for chronic spinal pain at cervical, thoracic, and lumbar levels. Ultrasound‑guided facet joint or medial branch injections are specifically identified among procedures considered unproven and not medically necessary, and the policy references the preference for fluoroscopy or CT when precise needle placement is required.

Additionally, medial branch block injections with local anesthetic volume greater than 0.5 mL, repeat therapeutic injections after two prior injections at the same level/side, and procedures performed when radiofrequency ablation is not being considered are included in the not‑covered examples.

OpenPayer

Facet Joint and Medial Branch Block Injections for Spinal Pain (for Nebraska Only)